The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies

Bonanni, Paolo; Villani, Alberto; Scotti, Silvestro; Biasci, Paolo; Russo, Rocco; Maio, Tommasa; Rosati, Giovanni Vitali; Moscadelli, Andrea; Conforti, Giorgio; Azzari, Chiara; Ferro, António; Francia, F; Chiamenti, Giampietro; Barretta, M.; Castiglia, Paolo; Macrì, Pasquale Giuseppe; Conversano, Michele; Bozzola, Elena; Angelillo, Italo Francesco

doi:10.1016/j.vaccine.2021.01.019

Cited by 13 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of Herpes Zoster vaccines, probably the adjuvanted conjugate vaccine could be the best choice for people affected by primary or secondary immunodepression and the offer of this vaccination for this target group (in particular for young people, actually not included in the National Immunization Schedule [15] ) must be accelerated; on the other side, the use of live-attenuated vaccine could be evaluated for the universal mass vaccination of older people, in particular considering the cost of the two vaccines currently available.…”

Section: Bodymentioning

confidence: 99%

The public health and the question of the “best vaccine”

Tafuri¹,

Bianchi²,

Stefanizzi³

2022

Vaccine

View full text Add to dashboard Cite

Section: Bodymentioning

confidence: 99%

The public health and the question of the “best vaccine”

Tafuri¹,

Bianchi²,

Stefanizzi³

2022

Vaccine

View full text Add to dashboard Cite

“…Most high-income countries, including Italy (Figure 5), have developed recommendations for adult (≥19 years) vaccinations [8,19,20,[86][87][88][89]. The Italian Ministry of Health recommends the periodic vaccination (every 10 years) of all adults, as well as all women during each pregnancy, with the combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine, as well as MMR and varicella vaccination for adults who have no history of contracting the diseases or relevant previous vaccinations [20].…”

Section: Vaccination Recommendationsmentioning

confidence: 99%

Manifesto on the Value of Adult Immunization: “We Know, We Intend, We Advocate”

Incalzi

Blasi

Conversano³

et al. 2021

Vaccines

View full text Add to dashboard Cite

Immunization through vaccination is a milestone achievement that has made a tremendous contribution to public health. Historically, immunization programs aimed firstly to protect children, who were disproportionally affected by infectious diseases. However, vaccine-preventable diseases can have significant impacts on adult mortality, health, and quality of life. Despite this, adult vaccinations have historically been overlooked in favor of other health priorities, because their benefits to society were not well recognized. As the general population is aging, the issue of vaccination in older adults is gaining importance. In high-income countries, recommendations for the routine vaccination of older adults have been gradually introduced. The Italian National Immunization Plan is considered to be among the most advanced adult vaccination plans in Europe. However, available data indicate there is low adherence to vaccination recommendations in Italy. The COVID-19 pandemic has exposed the damage that can be caused by an infectious disease, especially among adults and individuals with comorbidities. The aim of this “Manifesto”, therefore, is to provide an overview of the existing evidence on the value of adult vaccination, in the Italian context, with a call to action to healthcare providers and health authorities.

show abstract

“…For this reason, we recommend to start the vaccination schedule from the sixth week of life". 8 The authors also discuss the impact of the maximum age for series completion on averted cases: "If we consider the maximum vaccination periods, i.e., 24 weeks (HRV) [RV1] or 32 weeks (HBRV) [RV5], a delay of 8 weeks may lead to an estimate of approximately 120 unprevented hospitalizations due to RVGE per year". 1 Such calculations do not reflect the established epidemiology of the disease, and vaccine efficacy and effectiveness estimates from clinical trials and observational studies that show high vaccination effectiveness after the first dose.…”

Section: Letter To the Editormentioning

confidence: 99%